Multiple System Atrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Multiple System Atrophy Market was valued at USD 149.73 Million in 2024, and is expected to reach USD 177.86 Million by 2030, rising at a CAGR of 3.11%. The global Multiple System Atrophy (MSA) market is experiencing significant expansion due to the growing prevalence of this rare, progressive neurodegenerative disorder and the increasing demand for effective diagnostic and therapeutic solutions.

MSA, which involves the degeneration of nerve cells in the brain and affects multiple systems such as motor control, autonomic functions, and coordination, currently lacks a cure, creating a notable unmet need for innovative treatments and diagnostic tools. MSA is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. Symptoms tend to appear in a person's 50s and advance rapidly over the course of five to 10 years. A person with MSA will have increased difficulty with movement and eventually become bedridden. People with MSA often develop swallowing problems that can lead to pneumonia in the later stages of the disease.

Advancements in biomarkers and diagnostic technologies are enhancing early detection and improving the accuracy of MSA diagnoses, which is expected to lead to earlier interventions, better patient outcomes, and the development of targeted therapies. Increasing collaborations between biotechnology firms, research institutions, and healthcare organizations are accelerating the development of MSA-specific treatments, with growing investment in both preclinical and clinical research expected to expand the pipeline of potential therapies.

North America leads the MSA market, driven by robust healthcare infrastructure, rising research and development activities, and heightened patient awareness. However, the main challenges in the market are the absence of a definitive cure and the complexity of treating a multi-system disorder. The rarity of MSA further complicates the development of therapies and diagnostic tools. Nevertheless, advancements in precision medicine, stem cell therapies, and gene editing technologies offer substantial opportunities to transform the treatment landscape. The global MSA market is positioned for steady growth, supported by ongoing scientific progress, increased patient awareness, and the continued pursuit of effective treatments.

Key Market Drivers

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are poised to propel the growth of the Global Multiple System Atrophy (MSA) Market by enhancing early detection and accuracy in disease diagnosis. Cutting-edge diagnostic tools, such as advanced imaging techniques and biomarker identification, enable healthcare professionals to detect MSA at earlier stages, facilitating timely intervention and management. Accurate and swift diagnosis is critical in addressing Multiple System Atrophy, a rare neurodegenerative disorder with diverse clinical presentations. The integration of innovative diagnostic methods not only aids in precise disease identification but also contributes to the development of targeted therapeutic strategies.

As these technologies become more sophisticated, they enhance the overall efficiency of clinical trials, expediting the approval process for novel MSA treatments. In October 2024, Sunbird Bio announced new data highlighting the effectiveness of its blood biomarker technology in detecting the aggregation of alpha-synuclein (α-synuclein) in the brain through a simple blood draw. The study results, set to be presented in a poster session on October 31 at the Clinical Trials on Alzheimer’s Disease (CTAD) international conference, showcase the potential of Sunbird’s diagnostic technology to accurately identify multiple neurodegenerative diseases, including Parkinson’s disease and multiple system atrophy.

These advancements in diagnostic technologies offer the promise of a non-invasive, blood-based approach for diagnosing these conditions, marking a significant step forward in the early detection and accurate diagnosis of neurodegenerative diseases. Improved diagnostic capabilities attract increased investments in research and development, fostering collaboration between pharmaceutical companies and healthcare institutions. This synergy accelerates the development of groundbreaking therapies, fostering a conducive environment for market growth. In essence, the symbiotic relationship between diagnostic advancements and therapeutic innovations is set to reshape the landscape of the Global Multiple System Atrophy Market, creating opportunities for stakeholders and improving patient outcomes.

Rising Research and Development Investments

The growth of the Global Multiple System Atrophy (MSA) Market is poised to be significantly influenced by the upsurge in Research and Development (R&D) investments. Increased financial commitments to R&D initiatives underscore a commitment to advancing our understanding of MSA and developing novel therapeutic interventions. Pharmaceutical companies and research institutions are allocating substantial resources to explore innovative treatment modalities, biomarkers, and diagnostic technologies. In May 2024, an international team of scientists made a groundbreaking discovery, identifying genetic risk factors for multiple system atrophy (MSA), a condition previously thought to have no genetic basis.

The study, published in Neuron, involved whole genome sequencing of 888 MSA cases of European ancestry and 7,128 control samples. Researchers pinpointed four loci on the genome significantly linked to MSA development. Additionally, RNA analysis revealed that mutations in the USP38-DT, KCTD7, and lnc-KCTD7-2 genes increased susceptibility to MSA. This study highlights the growing importance of research and development investments in understanding the genetic underpinnings of complex diseases like MSA. Supported by grants from the National Institute on Aging (RF1 AG057474 and U01 AG061356) and the NUgene Project, which provided MSA patient samples, these findings underscore the value of continued funding in advancing scientific knowledge and uncovering new therapeutic targets for neurodegenerative diseases. This discovery could lead to more targeted approaches in both diagnosing and treating MSA, marking a significant milestone in the field of neurogenetics.

Rising R&D investments contribute to the acceleration of clinical trials, facilitating the swift development and regulatory approval of potential MSA treatments. This influx of funds fosters collaboration among industry players, leading to synergies in expertise and resources. Furthermore, heightened R&D spending attracts top-tier talent and fosters a culture of innovation within the scientific community, propelling breakthrough discoveries and advancements in MSA research.

In November 2023, Asklepios BioPharmaceutical, Inc. (AskBio) announced that the first patient had been randomized in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy under development for the treatment of multiple system atrophy-parkinsonian type (MSA-P). This marks a key milestone in the advancement of AB-1005, which uses an adeno-associated viral vector to deliver glial cell line-derived neurotrophic factor (AAV2-GDNF) to the putamen. The progression of this clinical trial underscores the growing focus on research and development investments aimed at innovative treatments for neurodegenerative diseases.

The trial's progress brings this promising gene therapy closer to potentially offering a new therapeutic option for MSA-P patients, illustrating the vital role of R&D funding in advancing cutting-edge treatments. The positive impact of these investments extends beyond scientific progress, creating a conducive market environment by boosting investor confidence and attracting additional funding. In essence, the escalating R&D investments in the MSA space not only drive scientific innovation but also play a pivotal role in shaping the future landscape of the Global Multiple System Atrophy Market, offering hope for improved patient outcomes and therapeutic solutions.

Collaborative Initiatives and Partnerships

Collaborative initiatives and partnerships are set to be key drivers in propelling the growth of the Global Multiple System Atrophy (MSA) Market. In an era of complex healthcare challenges, strategic alliances between pharmaceutical companies, research institutions, and advocacy groups are becoming increasingly prevalent. These partnerships foster a shared pool of resources, expertise, and data, creating synergies that accelerate the development of innovative solutions for MSA. Pooling knowledge and capabilities through collaborations enables faster progress in research and development efforts, leading to more efficient clinical trials and the timely introduction of new therapies.

Joint initiatives also mitigate risks and financial burdens, allowing stakeholders to navigate the intricate landscape of MSA research collectively. Furthermore, collaborative efforts enhance the credibility and robustness of scientific findings, which is crucial for regulatory approvals and market acceptance. By establishing a network of shared objectives, these partnerships create a supportive ecosystem for sustained advancements, attracting further investments and fostering a competitive yet cooperative environment within the Global Multiple System Atrophy Market. In essence, collaborative initiatives are pivotal in driving the industry forward, ensuring that the collective pursuit of solutions for MSA remains at the forefront of global healthcare innovation.

Key Market Challenges

Diagnostic Complexity and Variability

The growth of the Global Multiple System Atrophy (MSA) Market may face hindrances due to the diagnostic complexity and variability inherent in the disease. MSA presents a spectrum of clinical manifestations that often overlap with other neurodegenerative disorders, posing challenges in accurate and timely diagnosis. The intricacies and subtleties of MSA symptoms can lead to misdiagnoses or delayed identification, impacting the initiation of appropriate treatments. The lack of standardized diagnostic criteria further contributes to variability in clinical assessments, hindering the consistency needed for effective research, drug development, and regulatory processes.

This diagnostic uncertainty may deter investment and slow down the overall pace of innovation within the MSA market, as pharmaceutical companies and investors may be cautious about the inherent challenges in navigating such diagnostic complexities. Additionally, the variability in disease presentation among individuals makes it challenging to conduct uniform clinical trials and stratify patient populations accurately. This complexity could impede the development of targeted therapies, as a clear understanding of the disease spectrum is crucial for designing effective interventions. Thus, addressing the diagnostic intricacies of MSA is essential to unlock the full growth potential of the Global Multiple System Atrophy Market.

High Research and Development Risks

The Global Multiple System Atrophy (MSA) Market faces hindrances in growth due to the high research and development (R&D) risks associated with addressing this complex neurodegenerative disorder. Developing effective treatments for MSA demands substantial investment in R&D, often with uncertain outcomes. The intricate nature of the disease, coupled with the lack of comprehensive understanding of its underlying mechanisms, amplifies the inherent risks in drug development. Investors and pharmaceutical companies may be deterred by the considerable uncertainty in achieving successful outcomes during clinical trials.

High R&D risks contribute to extended timelines, increased costs, and the potential for failures at various stages of development, posing financial challenges and diminishing the attractiveness of MSA-focused projects. Furthermore, the absence of clear biomarkers and standardized diagnostic criteria for MSA adds an additional layer of complexity, making it difficult to measure treatment efficacy accurately. This uncertainty may discourage stakeholders from committing resources to projects with unpredictable outcomes. Mitigating these high R&D risks requires collaborative efforts, increased understanding of disease pathology, and innovative approaches, as overcoming these challenges is essential for unlocking the growth potential of the Global Multiple System Atrophy Market.

Key Market Trends

Personalized Medicine and Precision Therapeutics

Personalized medicine and precision therapeutics are poised to drive significant growth in the Global Multiple System Atrophy (MSA) Market. As advancements in medical research continue, there is a growing emphasis on tailoring treatments to the unique genetic, molecular, and clinical characteristics of individual patients. This approach allows for more targeted interventions, optimizing therapeutic outcomes for those afflicted with MSA. By leveraging personalized medicine, pharmaceutical companies can develop treatments that address specific subtypes or variations within the MSA patient population. In May 2023, Theravance Biopharma, Inc. announced that the U.S.

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This designation highlights the potential of ampreloxetine as a targeted therapeutic option for a rare and underserved condition, aligning with the growing trend of personalized medicine and precision therapeutics. By focusing on specific patient populations and conditions like nOH in MSA, therapies like ampreloxetine reflect a shift toward more tailored, effective treatments that address the unique needs of individuals, improving outcomes and advancing the field of precision medicine.

Precision therapeutics, guided by biomarker identification and genetic profiling, enable the design of therapies that are not only more effective but also have fewer side effects, enhancing overall patient quality of life. The implementation of personalized medicine strategies in MSA research and drug development enhances the efficiency of clinical trials, as patient cohorts can be more precisely defined based on their genetic and molecular profiles. This not only expedites the approval process but also fosters a more favorable regulatory environment. In essence, the integration of personalized medicine and precision therapeutics is poised to revolutionize the Global Multiple System Atrophy Market, offering tailored solutions that not only address the complexities of the disease but also pave the way for more successful and efficient therapeutic interventions.

Rise of Digital Health Solutions

The ascent of digital health solutions is set to be a driving force in the growth of the Global Multiple System Atrophy (MSA) Market. Advanced technologies, such as telemedicine, remote monitoring, and digital diagnostics, are transforming the landscape of healthcare delivery, providing novel avenues for MSA management. Digital health solutions offer the potential to enhance patient care through remote monitoring of symptoms, facilitating real-time data collection and analysis. This not only enables healthcare professionals to gain deeper insights into the progression of MSA but also allows for more proactive and personalized interventions.

Telehealth platforms create opportunities for improved patient engagement, enabling individuals with MSA to access specialized care remotely. This not only addresses geographical barriers but also enhances the overall efficiency of healthcare delivery. Moreover, the integration of digital health tools in clinical trials enhances the precision and reliability of data collection, expediting the research and development process for new MSA treatments. As the healthcare industry increasingly embraces digital solutions, the Global Multiple System Atrophy Market stands to benefit from heightened efficiency, improved patient outcomes, and accelerated innovation in the quest for effective therapies.

Segmental Insights

Diagnosis Insights

Based on Diagnosis, the Magnetic Resonance Imaging (MRI) emerged as the fastest growing segment in the global market for Multiple System Atrophy during the forecast period. MRI provides non-invasive, high-resolution imaging that is essential for diagnosing MSA, allowing healthcare professionals to detect structural changes and brain atrophy associated with the condition. Given that MSA affects multiple brain regions, MRI’s ability to capture these changes in detail makes it a critical tool for accurate diagnosis. Advances in MRI technology, such as enhanced imaging quality and faster scan times, are driving its increased use in diagnosing MSA.

New MRI techniques like functional MRI (fMRI) and diffusion tensor imaging (DTI) offer greater sensitivity in detecting early brain changes, which is particularly valuable for neurodegenerative diseases like MSA. MRI is often used in conjunction with other diagnostic methods, supporting more accurate and comprehensive diagnoses. Combined with clinical assessments, MRI helps differentiate MSA from other neurodegenerative diseases, leading to more reliable diagnoses and improved patient outcomes. As awareness of MSA grows, there is a stronger focus on early detection to enable more effective treatment. MRI is crucial in identifying brain abnormalities in the early stages of MSA, facilitating earlier intervention and better management. As a result, the MRI segment in the MSA market is experiencing significant growth, driven by its pivotal role in the accurate, early, and non-invasive diagnosis of the disease.

End User Insights

Based on End User, Hospitals emerged as the dominating segment in the global market for Multiple System Atrophy in 2024. Hospitals are equipped with state-of-the-art diagnostic technologies, including MRI, PET scans, and other imaging tools, essential for the accurate diagnosis of MSA. Furthermore, they house specialized departments such as neurology and radiology, offering expert knowledge in managing neurodegenerative conditions. Given that MSA is a complex, multi-system disorder, effective treatment requires a multidisciplinary approach. Hospitals are well-positioned to provide this level of care, with access to a wide range of specialists, including neurologists, cardiologists, and physiotherapists, ensuring holistic management of the disease across various symptoms and stages.

In addition, hospitals have the infrastructure to administer advanced therapies and conduct clinical trials for MSA, offering access to specialized treatments, experimental therapies, and investigational drugs. They also have the capacity to monitor patient progress using comprehensive clinical tools. Many hospitals, particularly large academic centers, are heavily involved in research and clinical trials, which play a key role in developing new treatments for MSA, offering patients access to cutting-edge therapies that may not be available in smaller outpatient settings. MSA patients may experience sudden health complications or rapid disease progression, necessitating immediate medical attention. Hospitals provide the critical emergency and inpatient services required to manage these acute needs, services that smaller centers may lack. As a result, hospitals possess the resources, expertise, and facilities required to effectively address the complex needs of MSA patients, making them the leading end-users in the market.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Multiple System Atrophy Market in 2024. North America, particularly the United States, boasts a highly advanced healthcare system equipped with cutting-edge diagnostic tools, treatment facilities, and research institutions. This robust infrastructure plays a pivotal role in the efficient diagnosis and management of complex diseases like MSA. The U.S. Food and Drug Administration (FDA) offers a well-structured regulatory environment that facilitates the approval of new therapies and diagnostic tools, encouraging the development of innovative treatments for MSA and other neurodegenerative disorders, thus ensuring faster access to these therapies for patients.

In January 2025, with support from the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH), the implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act will be led. Signed into law on July 2, 2024, this legislation aims to establish a Federal Advisory Council on Parkinson's Research, Care, and Services, and calls for the creation of a comprehensive national plan to address Parkinson's disease and other neurodegenerative Parkinsonisms, such as MSA, corticobasal degeneration, progressive supranuclear palsy, and Parkinson's-related dementia.

North America is home to numerous leading medical centers and academic hospitals, which are actively engaged in clinical trials for new MSA therapies and technologies. This enables regional patients to access the latest advancements in treatment, further propelling market growth. The region’s aging population is also contributing to a rising incidence of neurodegenerative diseases like MSA, leading to greater demand for specialized care and treatments, thereby strengthening North America's position in the global market. Together, these factors make North America the dominant player in the MSA market, with its strong healthcare infrastructure, substantial research investments, and increasing need for innovative diagnostic and therapeutic solutions.

Key Market Players

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA.

Report Scope:

In this report, the Global Multiple System Atrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiple System Atrophy Market, By Diagnosis:

• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Tilt Table Test
• Others

Multiple System Atrophy Market, By Age:

• Pediatric
• Adults
• Geriatric

Multiple System Atrophy Market, By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Multiple System Atrophy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiple System Atrophy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.